Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Status:
Completed
Trial end date:
2019-11-15
Target enrollment:
Participant gender:
Summary
Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth. It may also make tumor cells more sensitive to radiation therapy. Radiation therapy
uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as
temozolomide, work in different ways to stop the growth of tumor cells, either by killing the
cells or by stopping them from dividing. This randomized phase I/II trial is studying the
best dose of dasatinib and to see how well it works compared with a placebo when given
together with radiation therapy and temozolomide in treating patients with newly diagnosed
glioblastoma multiforme.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Alliance for Clinical Trials in Oncology
Collaborators:
Bristol-Myers Squibb National Cancer Institute (NCI)